<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="106076">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02147262</url>
  </required_header>
  <id_info>
    <org_study_id>ACA-0613</org_study_id>
    <nct_id>NCT02147262</nct_id>
  </id_info>
  <brief_title>Laboratory Characteristics in Chronic Atrophic Acrodermatitis</brief_title>
  <official_title>Inflammatory Proteins,Gene Polymorphisms, and Transcriptome Profiles in Patients With Chronic Atrophic Acrodermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Ljubljana School of Medicine,  Slovenia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harvard University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Centre Ljubljana</source>
  <oversight_info>
    <authority>Slovenia: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to characterize the inflammatory proteins, gene
      polymorphisms, and transcriptome profiles in patients with chronic atrophic dermatitis to
      gain better insight into pathogenesis of chronic infection with Borrelia burgdorferi sensu
      lato.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>inflammatory proteins in patients with chronic atrophic dermatitis</measure>
    <time_frame>up to  24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The inflammatory immune profiles will be assessed using Luminex to measure the expression of cytokines and chemokines representative of innate and adaptive TH1, TH2, TH17, and B cell responses.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical characteristics of patients with chronic atrophic dermatitis treated with doxycycline for 14 or 28 days</measure>
    <time_frame>at enrollment, at 2, 6 12 and 24 months follow-up</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>gene polymorphisms in patients with chronic atrophic dermatitis</measure>
    <time_frame>at enrollment, at 6 months follow-up</time_frame>
    <safety_issue>No</safety_issue>
    <description>The expression of disease-relevant genomic variants will be assessed using ImmunoChip.</description>
  </other_outcome>
  <other_outcome>
    <measure>transcriptome profiles in patients with chronic atrophic dermatitis</measure>
    <time_frame>at enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will use RNA sequencing of individual immune cell subtypes from patients to determine their transcriptome.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chronic Atrophic Acrodermatitis</condition>
  <arm_group>
    <arm_group_label>ACA-doxy 14 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients with chronic atrophic acrodermatitis treated with doxycycline for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACA-doxy 28 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients with chronic atrophic acrodermatitis treated with doxycycline for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxycycline orally, 100 mg, bid, 14 days</intervention_name>
    <arm_group_label>ACA-doxy 14 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxycycline orally, 100 mg, bid, 28 days</intervention_name>
    <arm_group_label>ACA-doxy 28 days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  chronic atrophic dermatitis in patients &gt;18 years

        Exclusion Criteria:

          -  none
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franc Strle, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>UMC Ljubljana</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dasa Stupica, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Ljubljana</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dasa Stupica, MD, PhD</last_name>
    <phone>+386 1 522 2110</phone>
    <email>cerar.dasa@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Franc Strle, MD, PhD</last_name>
    <phone>+386 1 522 2610</phone>
    <email>franc.strle@kclj.si</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UMC Ljubljana, Department of Infectious Diseases</name>
      <address>
        <city>Ljubljana</city>
        <zip>1525</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dasa Stupica, MD,PhD</last_name>
      <phone>+386 1 522 2110</phone>
      <email>cerar.dasa@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Franc Strle, MD,PhD</last_name>
      <phone>+386 1 522 2610</phone>
      <email>franc.strle@kclj.si</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 23, 2014</lastchanged_date>
  <firstreceived_date>June 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Ljubljana</investigator_affiliation>
    <investigator_full_name>Franc Strle</investigator_full_name>
    <investigator_title>M.D., PhD</investigator_title>
  </responsible_party>
  <keyword>chronic atrophic acrodermatitis</keyword>
  <keyword>Lyme borreliosis</keyword>
  <keyword>molecular characteristics</keyword>
  <keyword>outcome</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acrodermatitis</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Doxycycline hyclate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
